ABSTRACT
ABSTRACT The aim of this study has been to study whether the top-down method, based on the average value identified in the Brazilian Hospitalization System (SIH/SUS), is a good estimator of the cost of health professionals per patient, using the bottom-up method for comparison. The study has been developed from the context of hospital care offered to the patient carrier of glucose-6-phosphate dehydrogenase (G6PD) deficiency with severe adverse effect because of the use of primaquine, in the Brazilian Amazon. The top-down method based on the spending with SIH/SUS professional services, as a proxy for this cost, corresponded to R$60.71, and the bottom-up, based on the salaries of the physician (R$30.43), nurse (R$16.33), and nursing technician (R$5.93), estimated a total cost of R$52.68. The difference was only R$8.03, which shows that the amounts paid by the Hospital Inpatient Authorization (AIH) are estimates close to those obtained by the bottom-up technique for the professionals directly involved in the care.
RESUMO A pesquisa teve por objetivo estudar se o macrocusteio, baseado no valor médio identificado no Sistema de Internação Hospitalar (SIH/SUS), constitui um bom estimador do custo de profissionais de saúde por paciente, tendo como comparação o método de microcusteio. O estudo foi desenvolvido no contexto da assistência hospitalar oferecida ao portador da deficiência de glicose-6-fosfato desidrogenase (dG6PD) do sexo masculino com evento adverso grave devido ao uso da primaquina, na Amazônia Brasileira. O macrocusteio baseado no gasto em serviços profissionais do SIH/SUS, como proxy desse custo, correspondeu a R$60,71, e o microcusteio, baseado nos salários do médico (R$30,43), do enfermeiro (R$16,33) e do técnico de enfermagem (R$5,93), estimou um custo total de R$52,68. A diferença foi de apenas R$8,03, mostrando que os valores pagos pela Autorização de Internação Hospitalar (AIH) são estimadores próximos daqueles obtidos por técnica de microcusteio para os profissionais envolvidos diretamente no cuidado.
Subject(s)
Humans , Male , Adult , Primaquine/adverse effects , Hospital Costs/statistics & numerical data , Glucosephosphate Dehydrogenase Deficiency/economics , Glucosephosphate Dehydrogenase Deficiency/drug therapy , Hospitalization/economics , Antimalarials/adverse effects , Patient Care Team/economics , Primaquine/economics , Time Factors , Brazil , Malaria/diet therapy , Malaria/economics , National Health Programs/economics , Antimalarials/economicsABSTRACT
Se estudiaron 8 pacientes con el diagnóstico de paludismo por Plasmodium vivax y deficiencia de glucosa 6 fosfato deshidrogenasa, que debían recibir tratamiento radical antipalúdico con primaquina. Se determinó que el 87,5 por ciento de los paciente presentó hemólisis, pero la relación de ésta con la actividad enzimática no fue significativa (p < 0,05) el 50 por ciento de los pacientes no pudo concluir el tratamiento por la aparición de hemólisis importante. Concluimos que en los pacientes con déficit de glucosa 6 fosfato deshidrogenasa no debe hacerse uso indiscriminado de la primaquina
Subject(s)
Glucosephosphate Dehydrogenase Deficiency/drug therapy , Hemolysis , Malaria/drug therapy , Plasmodium vivax , Primaquine/therapeutic use , CubaABSTRACT
32 subjects with Plasmodium falciparum gametocytes, and 31 cases with Plasmodium vivax infection from two military hospitals (Lashio, Mandalay) were treated with quinine 600 mg three times a day for 7 days followed by primaquine 45 mg single dose for gametocytes and 45 mg weekly x 8 weeks for vivax malaria. Although screening of red cell glucose-6-phosphate dehydrogenase (G6PD) was done prior to primaquine treatment, G6PD deficient subjects were not excluded from the trial. 20 patients hemizygous for mild G6PD deficiency (GdB- variant), 2 patients hemizygous for severe deficiency (Gd-Myanmar variant) completed the trial. No case of acute hemolysis was observed in all 22 patients with two genotypes of red cell G6PD deficiency status. Therefore, a single dose of primaquine 45 mg and/or weekly for 8 weeks is adequate for the treatment of patients with P. falciparum gametocytes and/or P. vivax malaria ignoring these red cell G6PD enzyme deficient variants in Myanmar.